Five things for pharma marketers to know: Tuesday, May 2, 2023

Five things for pharma marketers to know:

1. Johnson & Johnson announced its bladder cancer treatment known as “the pretzel” has shown promise in a Phase II study called SunRISe-1.

2. Late-stage clinical biopharma company Acelyrin said that it was seeking a valuation of up to $1.5 billion in its initial public offering.

3. The Food and Drug Administration declined to approve Ascendis Pharma’s experimental hormone disorder therapy, TransCon PTH.

4. Senators crafting legislation that would reform the practices of pharmacy benefit managers have delayed the effective date by 10 months.

5. A study showed that OpenAI’s ChatGPT tool may display more empathy than doctors when it comes to answering patient questions.